Eli Lilly and Company (NYSE:LLY) Shares Acquired by New Century Financial Group LLC

New Century Financial Group LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 10.0% during the second quarter, Holdings Channel reports. The firm owned 2,185 shares of the company’s stock after acquiring an additional 199 shares during the period. Eli Lilly and Company makes up approximately 0.8% of New Century Financial Group LLC’s portfolio, making the stock its 20th largest position. New Century Financial Group LLC’s holdings in Eli Lilly and Company were worth $1,978,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Lynx Investment Advisory acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $32,000. LGT Financial Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $36,000. Morton Brown Family Wealth LLC raised its stake in shares of Eli Lilly and Company by 45.5% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after buying an additional 15 shares during the period. Core Wealth Advisors Inc. raised its stake in shares of Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after buying an additional 32 shares during the period. Finally, Unique Wealth Strategies LLC acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $45,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 52,369 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $915.18, for a total value of $47,927,061.42. Following the transaction, the insider now directly owns 97,247,403 shares in the company, valued at approximately $88,998,878,277.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders have sold 364,810 shares of company stock worth $339,366,198. 0.13% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages have recently weighed in on LLY. Barclays upped their target price on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Bank of America boosted their price target on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Truist Financial reiterated a “buy” rating and set a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Guggenheim boosted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Finally, JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $977.35.

Eli Lilly and Company Trading Up 0.9 %

LLY opened at $885.56 on Tuesday. Eli Lilly and Company has a one year low of $516.57 and a one year high of $972.53. The company has a market cap of $841.64 billion, a P/E ratio of 130.42, a PEG ratio of 2.78 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The business’s 50-day simple moving average is $896.50 and its 200-day simple moving average is $844.99.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. As a group, equities research analysts expect that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.